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ABSTRACT
Measuring the lifetime costs and benefits of medical technologies is essential in evaluating technological
change and determining the productivity of medical care.  Using data on Medicare beneficiaries with
a heart attack in the late 1980s and 17 years of follow up data, I evaluate the long-term costs and benefits
of revascularization after a heart attack.  I account for non-random selection into treatment with instrumental
variables; following McClellan, McNeil, and Newhouse, the instrument is the differential distance
to a hospital capable of providing revascularization.  The results show that revascularization is associated
with over 1 year of additional life expectancy, at a cost of about $40,000. Revascularization, or other
treatments correlated with it, appears to be highly cost-effective.
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Technological change is the predominant reason for medical cost increases in the 
past half century.  Studies of aggregate medical spending and of particular medical 
conditions show that at least half of all cost growth is a result of increased use of 
technology (Newhouse, 1992; Cutler and McClellan 2001). 
But evaluating the short run cost of technology is not the only policy need.  There 
are two other issues that also need to be considered.  The first is the health benefits that 
result from technology.  Medical technology may be expensive, but it might still be a 
good deal, if it extends the length or quality of life or otherwise results in positive social 
returns.  Understanding cost-effectiveness is more important than understanding costs 
alone. 
Even in the cost realm, short run costs are only a partial story.  Medical advances 
applied in one year can lead to higher or lower spending in subsequent years.  Costs 
subsequently may increase if people survive to spend more, or may fall if people live 
healthier lives and thus use less care.  These downstream impacts of new technology need 
to be evaluated in addition to the up front costs.  Indeed, it is possible for new technology 
to lower future spending, if the improved health that results from it offsets the increase in 
spending over the longer number of years. 
In this paper, I consider the lifetime costs and benefits of medical technology.  I 
first show theoretically how to measure the impact of medical technology on lifetime 
medical spending, and the long-run cost effectiveness of new technology.  I then turn to a 
specific medical technology: therapeutic surgical care after a heart attack.  In the 
aftermath of a heart attack, many people will receive bypass surgery or angioplasty   2
(collectively termed revascularization) to restore blood flow to the heart.  Each is 
expensive, and the value of each has been debated (Skinner, Staiger, and Fisher, 2007).  I 
focus on the marginal value of receiving these intensive treatments.   
The central empirical issue in evaluating the impact of any technology is the non-
random selection of who receives the care.  The sickest patients may not be strong 
enough to withstand revascularization, and the healthiest patients may not need it.  Thus, 
the set of people receiving revascularization is not a random set of people with a heart 
attack.  McClellan, McNeil, and Newhouse (1994) account for this by instrumenting for 
receipt of the technology, using the differential distance from the patient’s zip code of 
residence to a hospital capable of providing the technology as the instrument.
1  I follow 
the same strategy in this paper. 
The advantage that I bring to these previous efforts is the ability to analyze 
outcomes over longer-periods of time.  McClellan, McNeil, and Newhouse (1994) used 
only four years of follow-up data on MI patients.   I take advantage of the greater elapsed 
time since their study was completed and use 17 years of data on MI cohorts.  This gives 
me a more complete lifetime spending and survival history for Medicare beneficiaries 
who had an MI in the late 1980s.   
Like McClellan, McNeil, and Newhouse (1994), I show that people who receive a 
revascularization procedure have lower mortality in the first day after the MI than those 
not receiving revascularization.  This may not be a result of revascularization; most 
revascularizations are not performed that rapidly.  Rather, it probably reflects selection or 
other correlated treatments.  However, this initial mortality benefit disappears by one year 
                                                 
1 Chandra and Staiger (2007) follow this strategy as well.  They use data fro the mid-1990s but have only 
one year of mortality follow-up.   3
after the MI; mortality is higher for the revascularization group at that point.  In 
subsequent years, revascularization is associated with reduced mortality, with an increase 
in their survival rate of 5 percentage points after 3 years and 12 percentage points after a 
decade.  Even 17 years after the MI, the survival benefit is 5 percentage points.   
While revascularization extends survival, it does not save money.  Receiving 
revascularization is associated with increased spending of about $40,000 after a decade, 
of which 60 percent comes in the immediate aftermath of the MI.  Still, the costs are 
small relative to the benefits.  I estimate that the cost of revascularization is about 
$33,000 per year of extra life. 
In contrast to these results for revascularization, I find very small survival benefits 
of being admitted to a high volume hospital, and significantly greater spending.  Survival 
rates in high volume hospitals are 2 percentage points higher in the period just after the 
MI, and half a percent higher after that.  The overall survival benefit is .07 years, at a 
cumulative cost of nearly $10,000 higher.  The cost-effectiveness is thus $144,000 per 
year. 
There are two possible interpretations of these results.  If one believes the 
instrumental variables, they suggest that intensive medical care in the aftermath of an MI 
is highly cost effective, even if it doesn’t save money.  It is possible, however, that the 
instrument is picking up other aspects of being admitted to a hospital with 
revascularization capability.  Revascularization hospitals may be better than hospitals 
without revascularization capability because they provide better medical management 
during the admission, because they are better at post-admission follow-up, or because 
people come to them for treatment of other conditions in subsequent years, and receive   4
better care at that point.  Adopting this formulation, the estimates suggest lower absolute 
mortality benefit, but about the same cost-effectiveness – $17,000 per year of additional 
life. 
The paper is structured as follows.  The first section considers the theoretical 
impact of medical technology on lifetime costs.  The second section describes the case 
study I consider.  The third section presents the data.  The fourth and fifth sections 
present the results, and the last section discusses the implications. 
 
I.  The Lifetime Impact of Medical Technology 
Imagine that a new medical technology is developed to treat people with a 
particular condition.  A natural desire is to estimate the costs and benefits of the new 
technology.  Short-run costs and health impacts are relatively easy to measure, if one has 
the right data.  One looks at how spending and health for people with the treatment 
compare to similar people without the treatment.  The major issue in this comparison is 
econometric: how to separate out the effect of the treatment from the factors that make 
someone more or less likely to receive the treatment or from other treatments correlated 
with the one under study.  I return to this below. 
But short-run costs and benefits are not the only concern.  A treatment provided in 
one year may have impacts on health and medical care received down the road, and this 
may increase or decrease the cost-effectiveness of the therapy.  Consider a technology s 
with upfront costs in year t of m*t.  I denote Is as an indicator for whether the technology 
is provided.  The technology affects health in the future, so Ht+k=Ht+k(Is), where Ht+k is 
health in year t+k.  Since future spending is related to future health status, this will have   5
impacts on future costs: mt+k=mt+k(Ht+k).  Substituting the recursive equations, the present 
value of lifetime medical spending is given by: 
∑
∞
=
+ +
− + + =
1
)) ( ( ) 1 ( ) (
k
s k t k t
k
s t I H m r I m Spending     (1) 
where r is the discount rate.  The first term in equation (1) is the direct cost of the 
technology.  The second term is the indirect cost, operating through subsequent health 
status.   
One can imagine situations where the second term is positive or negative.  A life 
saving intervention increases future costs.  Without the intervention, the person dies and 
future spending is zero.  With the intervention, the person survives.  Regardless of the 
health state of the survivor, there will be some medical spending.  Interventions that 
reduce disability, in contrast, could lower lifetime spending.  If the intervention results in 
fewer lifetime years spent disabled, or if death occurs at a later age and is thus cheaper, 
the total costs of caring for the person may decline.  This latter point is particularly 
important given the very high spending at the end of life.  Over one-quarter of Medicare 
spending is in the last year of life, so that interventions that make death cheaper could 
come with significant savings.   
Table 1 show the magnitude of this possible effect, using data from Hoover et al. 
(2002) on deaths in the mid-1990s.  Average spending in the last year of life is over 
$37,000, compared to $7,000 for people who do not die.  Total end of life costs are 
relatively constant by age.
2  Medicare costs, however, decline with age at death.  A 
Medicare beneficiary dying at age 85 or older spends nearly $10,000 less in the last year 
                                                 
2 One qualification to this finding is that people who die at older ages are more likely to have been in 
nursing homes, and at least some of the nursing home cost is for residential services.  Thus, the medical 
component of total end of life costs is probably falling with age.   6
of life than a beneficiary dying between 65 and 74.  Partly, this is because older people 
die of different diseases than younger people (pneumonia versus cancer, for example).  In 
addition, physicians are generally less aggressive in treating older people than treating 
younger people.  Since a good part of non-Medicare spending is paid for by the 
individual (out-of-pocket payments for nursing homes, for example), it is likely that total 
public spending declines with age at death.   
To see what this implies, consider an intervention that has a 10 percent chance of 
extending the life of an 80 year old by ten years.  The additional ten year survival lowers 
Medicare end of life costs by perhaps $8,000, or $800 for the population as a whole.  
Thus, the cost of the intervention could be as high as $800 without raising lifetime 
spending.
3  This is not a huge amount, but it is not trivial either. 
The counterpart to spending is health benefits.  Consider a particular 
normalization of Ht+k, scaled between 0 (death) and 1 (perfect health).  Quality adjusted 
life expectancy is given by: 
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Equation (2) shows the same discount rate for quality as for costs, but this needn’t be the 
case (Gold et al., 1996).   
  The cost-effectiveness of the technology can be found by taking the ratio of 
changes in equations (1) and (2):
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3 For simplicity, I ignore discounting in this example. 
4  See Meltzer (1997) for a similar derivation.   7
The numerator of equation (3) is the impact of the technology on medical spending, the 
sum of current and (discounted) future costs.  The denominator is the change in quality-
adjusted life expectancy. 
  An important issue in the analysis of lifetime costs and benefits is the treatment of 
downstream interventions.  Consider a specific example.  Suppose that bypass surgery 
keeps people alive and that some of those kept alive develop cancer.  The cancer may be 
more common in bypass surgery survivors (for example, smokers are differentially 
saved) or independent.  How does the treatment of cancer affect the cost-effectiveness of 
bypass surgery?   
  Much of the literature argues for omitting the future costs of unrelated diseases, 
arguing that this is irrelevant for considering the particular therapy under question (Gold 
et al., 1996).  Garber and Phelps (1997) justify this in a model without savings, though 
Meltzer argues that these costs need to be included if consumption is decided in an 
intertemporal framework.  Lee (forthcoming) suggests a distinction between future 
medical costs, which ought to be included, and future non-medical costs, which ought not 
to be included.  In my analysis, I consider the present value of future medical spending, 
but not non-medical spending.   
  Even when future costs are included, the importance of future diseases makes the 
evaluation of equation (3) complex.  Consider again the example of bypass surgery and 
downstream cancer.  Equation (3) might show a high cost effectiveness ratio (that is, 
large costs relative to the benefits) either because bypass surgery care is not very 
effective relative to its cost, or because cancer care is wasteful.  If the latter is the case,   8
one could make the wrong decision and decide not to provide bypass surgery, when the 
right decision is to provide bypass surgery but constrain cancer care.   
  There are some circumstances in which downstream costs will not be important.  
If cancer is equally likely to affect people who have bypass surgery and not, and the 
impact of cancer treatment is the same for people who have and have not received bypass 
surgery, then cancer costs and benefits will be the same for the bypass surgery group and 
the non-bypass surgery group, and the evaluation of bypass surgery will not be affected 
by subsequent cancer care.  Neither of these assumptions is likely to be true, however.  
Any intervention that affects mortality will almost certainly affect the probability of 
contracting other diseases.  Further, by affecting the subsequent path of health, bypass 
surgery may make future cancer care more or less likely to be successful.   
  In the absence of these assumptions, equation (3) can be interpreted as a weighted 
average of the costs and benefits of bypass surgery and all the subsequent conditions that 
are correlated with receiving bypass surgery.  As a result, one cannot necessarily attribute 
the estimate cost-effectiveness ratio as a causal statement about bypass surgery.  But even 
in this setting, it answers an important factual question: is it worth it to provide bypass 
surgery, given how people are treated on average as they age?  I discuss the interpretation 
of the findings in more depth below. 
 
II.  The AMI Example 
Most cost-effectiveness evaluations simulate the life course with and without the 
disease and use those simulations to estimate lifetime costs and benefits.  In some cases,   9
however, these data can be estimated directly, using longitudinal records on people with a 
particular condition.  I follow this latter path with the example of heart attacks.   
  Understanding a little medicine is helpful for following the analysis.  A heart 
attack occurs when the arteries supplying blood to the heart become occluded.  Restoring 
blood flow to the heart is the primary therapeutic goal for someone presenting with an 
MI.  This can be accomplished with medications, or through invasive surgical 
procedures.  Such procedures begin with a cardiac catheterization, a diagnostic procedure 
to measure blood flow to the heart.  Depending on the results, the cardiologist may decide 
to treat the patient medically, to perform coronary artery bypass grafting (CABG), or to 
use angioplasty (PCI), now done almost exclusively with stents.  Bypass surgery and 
angioplasty together are referred to as revascularization.  I consider the lifetime costs and 
benefits of revascularization. 
Because of its intensity, Medicare pays more for invasive care than for medical 
management.  Average costs in the 90 days after the MI are about $10,000 for patients 
who receive medical management, $15,000 for patients who are catheterized with no 
further procedure, $40,000 for patients who go on to receive CABG, and $20,000 for 
patients who receive an angioplasty.  These high dollar amounts make understanding the 
lifetime costs and benefits of revascularization particularly important.   
There is significant debate about the value of these procedures in the literature.  
Clinical studies generally show that bypass surgery and primary angioplasty (angioplasty 
done within the first hours of the MI) are associated with improvements in survival 
(Yusuf et al., 1994; Keeley et al., 2003), though non-primary angioplasty (done after the 
first few hours) is not (Hochman et al., 2006).  Clinical trials may not be relevant to real   10
world application, however, particularly for complex surgical interventions such as 
cardiac interventions.   
Existing literature analyzing data from actual practice has reached conflicting 
conclusions.  Studies of large changes in procedure use generally show significant health 
benefits.  Cutler and McClellan (2001) argue from aggregate data that advances in 
intensive treatments from 1984 to 1998 increased one-year survival by about 10 
percentage points and increased life expectancy by nearly one year, at a cost of only 
$10,000 – through Skinner, Stagier, and Fisher (2007) show that this progress stopped 
after 1998.  McClellan and Newhouse (1995) show that hospitals that open cardiac 
catheterization labs have 9 percentage points lower one year mortality rates; the cost per 
one year survivor is $70,000.  Similarly, Stukel et al. (2005) showed that areas that 
provided cardiac catheterization to more patients had 10 percent lower morality than 
areas with lower cardiac catheterization rates (roughly 4 percentage points with a 40 
percent one year mortality rate), though the difference narrowed in areas providing good 
medical management.   
There is more controversy about the benefits accruing to the marginal patient 
receiving intensive therapy.  Using data from 1987, McClellan, McNeil, and Newhouse 
(1994) estimate that people receiving cardiac catheterization because they lived closer to 
a facility providing it experienced 5 percentage points lower mortality a year after the MI, 
but most of this gain occurred during the first day, when catheterization would not be 
expected to provide significant benefit.  Chandra and Staiger (2007) repeat the analysis 
using data from the mid-1990s and estimate a 14 percentage point mortality advantage to 
cardiac catheterization.  The reconciliation between these studies is not entirely clear.   11
Beyond analysis of specific therapies, evidence shows clearly that not all care is 
worth it.  Skinner, Staiger, and Fisher (2007) document that areas with greater increases 
in spending on heart attacks did not experience greater outcomes – though spending 
increases are not very highly correlated with increased use of intensive procedures.  All 
of these considerations make an analysis of longer term outcomes important. 
 
III. Data 
The data I employ come from Medicare records.  I mirror as much as possible the 
work of McClellan, McNeil, and Newhouse (hereafter MMN).  MMN use data on all 
Medicare beneficiaries admitted to a hospital with a heart attack in 1987.  I do not have 
access to the complete set of MI patients, but I construct a similar sample using a 20 
percent sample of all Medicare beneficiaries.  Specifically, I sample all beneficiaries who 
were admitted to a hospital with a heart attack in 1986, 1987, or 1988 and use the same 
omission criteria as MMN to narrow down to non-repeat MIs.
5  The final sample size is 
124,950 patients. 
The advantage of my data is the additional years that have passed since the MMN 
analysis.  Where they are constrained to 4 year outcomes, I have complete histories 
through 2005.  I thus construct 17 year survival and cost experiences for people with an 
AMI in 1986-88.  By 17 years after the MI, nearly every Medicare beneficiary with a 
heart attack will have died. 
                                                 
5 I exclude people with an MI in the prior 365 days, people who were in the hospital for fewer than three 
days, other than those who died or were transferred, and people living more than 100 miles from the 
hospital of initial admission.  For the cost analysis, I exclude people who joined an HMO at any time after 
their MI, since spending data in HMOs are not reliably reported.  Given the sickness of these patients, this 
is not a large share of cases.   12
Data on procedure use are available in the Medicare claims.  In my primary 
results, I follow the bulk of the literature and examine receipt of revascularization 
procedure within 90 days of the MI.  This captures time for the initial survival therapy to 
be applied, and for others to receive procedures after a few weeks.  I show sensitivity 
results with a shorter window of time until the revascularization – 7 days and 30 days. 
In the late 1980s, about two-thirds of revascularization was bypass surgery; today, 
angioplasty is more common.  In my sample, about 30 percent of angioplasties were 
performed in the first day of the heart attack, and 70 percent were after that.  Since many 
of the first day angioplasties probably occurred many hours after the MI, the best way to 
view the sample is as predominantly non-primary angioplasty.   
Spending data are also from Medicare claims records.  Part A records are 
available for the entire 20 percent sample of Medicare beneficiaries.  Part B data are only 
available for 5 percent of beneficiaries, however.  To make spending as complete as 
possible, I use the smaller number of observations in the spending regressions 
(N=29,988).  The results using Part A data only for this simple are generally similar to 
those from the larger sample; this is not surprising given the large sample sizes. 
More troubling for the spending data is that they reflect only Medicare covered 
services; the Federal government does not match Medicare beneficiaries to non-Medicare 
spending.   Without any obvious source of non-Medicare data, I examine only Medicare 
spending.  All dollar amounts are adjusted to 2006 dollars using the GDP deflator. 
Revascularization is one factor that may affect health outcomes, but there are 
others as well.  Medical management of heart attacks involves a variety of medications 
(aspirin, beta-blockers, ACE inhibitors, and others) along with specialized facilities such   13
as coronary care units.  The Medicare data do not contain information on use of 
medications, so I cannot examine how they influence survival and costs.  One proxy for 
the general quality of heart attack care is the number of heart attack patients the hospital 
treated.  Providers with more experience have better outcomes than those with less 
experience (Huckman and Pisano, 2006).  Following MMN, I define a hospital as high 
volume if it admits at least 75 Medicare patients with heart attacks in the relevant year.
6   
The Medicare data have information on mortality but not quality of life.  I thus 
measure health only by whether the person survived.  Given the high mortality rate for 
people over 65 with an MI – 40 percent will die within one year – survival is an 
important measure of overall health.   
I relate survival and cumulative medical spending over k years to three sets of 
factors: demographic and health controls (X), a dummy variable for whether the patient 
received a revascularization procedure (REVASC), and a dummy variable for whether 
the patient was admitted to a high volume hospital (HIGH VOLUME).  The equations are 
of the form: 
Spendingi(k) =  Xiα
k + α1
k * REVASCi + α2
k * HIGH VOLUMEi + ηi (4)
 Mortalityi(k)  =  Xiβ
k + β1
k * REVASCi + β2
k * HIGH VOLUMEi + εi (5) 
By estimating these equations over different intervals, k, we can trace out the impact of 
revascularization and admission to a high volume hospital on lifetime health and medical 
spending. 
  The control variables (X) in equations (4) and (5) are in several categories.  Basic 
demographics include age by sex dummy variables (65-69, 70-74, 75-79, 80-84, 85+) and 
                                                 
6 Since I have a 20 percent sample of patients, I count hospitals as high volume if they have 15 admissions 
in the year.     14
dummies for black and other race.  I also include dummies for the year of the MI: 1986, 
1987, or 1988.  To capture the time from the MI until entering the medical system, I 
include distance to the nearest hospital and a dummy for rural residence.  Finally, to 
control for underlying health status, I include dummies for 24 comorbid conditions noted 
as secondary diagnoses on the MI admission or on a hospital admission in the prior year
7 
as well as total Medicare spending in the year prior to the MI.  
Several econometric issues arise in considering equations (4) and (5).  Equation 
(4) relates spending linearly to receipt of revascularization or admission to a high volume 
hospital.  Since entry into the sample is conditional on hospitalization, there is no need 
for a two-part model.
8  But there is an issue about whether spending is significantly right-
skewed, and if so whether a log transformation should be used.  In practice, results from 
logarithmic specifications gave very similar results.
9  For simplicity, I report the results 
for the level of spending.   
In the survival equation (5), an alternative to the cumulative survival function is to 
estimate a hazard model for death in any year.  By allowing for separate coefficients by 
year, I am effectively estimating a survival function with an unconstrained baseline.  I 
present the cumulative survival function and variations in that function based on receipt 
of revascularization and admission to a high volume institution. 
The major issue in estimating equations (4) and (5) is the endogeneity of 
revascularization and high volume hospital admission.  Conditional on having a heart 
                                                 
7 The list includes the categories from Elixhauser et al. (1998): congestive heart failure, valvular disease, 
pulmonary circulation disorders, peripheral vascular disorders, paralysis, other neurological disorders, 
chronic pulmonary disease, uncomplicated diabetes, complicated diabetes, renal failure, liver disease, 
peptic ulcer disease, HIV-AIDS, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid 
arthritis, coagulopathy, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, 
alcohol abuse, and psychoses.  
8 Effectively, the first part of the model – use of any medical care – is the same for everyone. 
9 I have also experimented with trimming large outliers in spending, again with similar impacts.   15
attack, very sick and very healthy patients are each less likely to receive intensive 
therapies.  The natural solution is instrumental variables.  I return to this below, after 
presenting OLS results.   
 
IV.  The Lifetime Consequences of AMI Treatment 
I begin with OLS estimates of the return to revascularization and being admitted 
to a high volume hospital.  These serve as a benchmark for the more appropriate 
instrumental variables.  Figure 1 shows OLS estimates of cumulative mortality for 
various years after the heart attack.  The scale for the revascularization coefficients is on 
the left hand side of the graph, and the scale for the high volume hospital coefficients is 
on the right hand side.  In each case the estimates are negative for all time periods – 
revascularization and admission to a high volume hospital always lower mortality.  But 
the revascularization coefficients in particular seem too large to be plausible.  The results 
suggest that revascularization reduces mortality by over 18 percent in the first 90 days 
and 20 percent after one year.  Clinical trials rarely show an impact of surgery that is this 
large or that immediate.  It seems clear that patient selection into treatment is non-
random.   
The solution to the endogeneity issue in MMN, which I follow, is to use 
instrumental variables.  MMN argue that the “differential distance” to a hospital capable 
of performing the indicated procedure – the distance to the nearest revascularization 
hospital minus the distance to the nearest hospital of any type – is a good instrument for 
actual receipt of the procedure.  This is true because patients are generally taken to the   16
nearest hospital after an MI, and where one is admitted affects what is done – even 
several months later.   
There are two important criteria for differential distance to be a good instrument.  
First, it needs to be the case that patients who are more likely to benefit from invasive 
treatments do not select their residential location based on distance to high-tech medical 
care.  There is no way to test this directly, though like MMN I show that most covariates 
are balanced above and below the median differential distance.   
The second criterion is that differential distance not be correlated with other 
treatments affecting outcomes.  For example, if hospitals that provide revascularization 
are also better at providing aspirin at admission, at managing post-acute follow-up, or at 
treating subsequent illnesses years later, the instrumental variables estimates will 
overstate the importance of revascularization.  This too is difficult to test, and worrisome 
because of the importance of a variety of other important therapies for AMI survival.  I 
return to the interpretation of the instrumental variable estimates below. 
The first stage equations are given by: 
   REVASCi  =  Xiγ  +  γ1*REVASC DIFFERENTIAL-DISTANCEi  +  νi   (6) 
   HIGH VOLUMEi  =  Xiδ  +  δ1*HIGH VOLUME DIFFERENTIAL-DISTANCEi  +  μi   (7) 
To form differential distance, I need to code hospitals as capable of providing 
revascularization or not.  Survey data on technological capabilities often have some error.  
To judge true revascularization capability, I see if the hospital performed at least 2 
procedures on Medicare beneficiaries in the indicated year.
10  This variable is allowed to 
change in the three year panel, though change is not rapid.
11 
                                                 
10 Requiring two procedures reduces the importance of solitary coding errors. 
11 About 2 percent of hospitals acquire revascularization capability over the time period.     17
  Receipt of a revascularization procedure is a binary variable, as is mortality.  In 
the absence of instrumental variables, the appropriate estimation of the mortality 
regression would be non-linear, for example a probit or logit specification.  In IV models, 
however, non-linear equations are problematic (Newey, 1990).  I thus estimate all of the 
models using linear probability equations.  
Table 2 reports summary information on the differential distance measures.  In the 
1986-88 period, the average differential distance to a hospital with revascularization 
capability is 8 miles, and the average differential distance to a high volume hospital is 2 
miles.  There is a good deal of heterogeneity in the differential distance measures.  The 
25
th percentile differential distance is 1 mile for revascularization and 0 miles for a high 
volume hospital.  The 75
th percentile is 30 miles for revascularization and 20 miles for 
high volume. 
While not everyone who is revascularized is admitted to a high volume hospital, 
high volume hospitals are far more likely to have revascularization capability.  The 
correlation between differential distance for revascularization and high volume hospital is 
.640.  I estimate the model with both variables included.  In specification tests, I included 
each variable separately.  The impact of revascularization or admission to a high volume 
hospital is similar with and without the other variable included.   
As noted above, one criterion for a valid instrument is that patients do not choose 
which hospital to live near on the basis of health status.   We can partially test this by 
looking at how observable risk factors are related to differential distance.  Table 3 shows 
differences in demographic characteristics of the population by differential distance to a 
hospital with revascularization capability, and a high volume of admissions.  In each   18
case, I cut the data about at the median.  The first rows report differences in 
demographics.  Because of the sample size, equality of the means for people who live 
closer and farther from the indicated hospitals is frequently rejected.  In most cases, 
however, the substantive differences are not large.  The major exception is urban or rural 
residence.  Many of those with high differential distance to a revascularization or high 
volume hospital live in rural areas.  To account for this, I include controls for distance to 
nearest hospital and rural residence in the regression. 
The next rows show that differential distance is associated with hospital of 
admission. People living below the median distance to a revascularization hospital are 38 
percentage points more likely to be initially admitted to a hospital capable of providing 
revascularization than are people who live farther away.  The difference in high volume 
admission based on above and below median distance to a high volume facility is 51 
percentage points. 
These differences in where people are admitted translate into differences in how 
they are treated.  People who live closer to a revascularization hospital are 3 percentage 
points more likely to receive a revascularization procedure than are people who live 
farther away.  Interestingly, living closer to a high volume hospital is not associated with 
increased likelihood of being revascularized.   
The next rows report cumulative mortality rates at different intervals after the MI: 
one day, 180 days, 1 year, 5 years, 10 years, and 17 years (the longest time period with 
complete data in the sample).  As in MMN, there is a large difference in mortality in 
favor of those living closer to a revascularization hospital.  However, the pattern is non-
linear.  In the first day after the MI admission, mortality rates are 1.1 percentage points   19
lower for people living closer to a revascularization hospital.  Given the infrequency of 
primary angioplasty in this time period, it is unlikely that this reflects the impact of 
revascularization.  Rather, it likely reflects unmeasured differences in patient 
characteristics, or other forms of therapy provided by hospitals that are capable of 
providing revascularization, such as greater use of aspirin or thrombolytic drugs.   
Beyond one day, the gap in mortality narrows so that by one year after the MI, 
there is no improvement in survival associated with living near a revascularization 
hospital.  Even the percentage difference (0.4 percentage points) is smaller.   After the 
one year interval, however, the gap in mortality again increases.  By 10 years after the 
MI, people living closer to a revascularization hospital are 0.5 percent more likely to 
survive than those living farther away.  This is true even with an 80 percent cumulative 
mortality rate.  The difference is relatively constant through 17 years.  It is more plausible 
that this reflects receipt of a revascularization procedure, although the case is not proven. 
If one believes that the difference in mortality ten years after the MI reflects the 
receipt of the revascularization, one can use Table 3 to estimate the marginal impact of 
that therapy.  The Wald estimate of the impact of revascularization on ten year survival is 
the mortality difference scaled by the difference in procedure receipt, or 17 percent 
(0.5/3.0).  This is a large impact.   
The impact of living near a high volume hospital follows a similar pattern.  There 
is a large mortality benefit of living near such an institution (1.3 percent) one day after 
the MI.  This might reflect better care provided by such institutions, or possibly selection 
of cases.  That gap remains roughly constant for the first year after the MI, and then 
narrows considerably.  By 10 years after the MI, the difference in mortality is 0.3 percent,   20
and is only significant at the 10 percent level.  Further, the Wald estimate of the impact of 
being admitted to a high volume hospital is much smaller – only 0.6 percent (0.3/51). 
The final set of rows shows the impact of differential distance on cumulative 
spending after the MI.  Spending is total expenditures up to that year; people who die are 
included in the sample, with their costs up to death included.  Spending is consistently 
higher for those living near a revascularization or high volume facility.  The difference in 
costs is about $3,000 in the 30 days after the MI, and increases to $9,000 by a decade 
later.  These differences in costs are sizeable.  The cost differences reflect two factors: 
more care provided to patients who live closer to hospitals with revascularization 
capability, and increased prices that Medicare pays for such hospitals (assuming these are 
teaching hospitals or hospitals that care for a disproportionate share of the poor).  
Typically, studies of variation in medical spending attribute a greater share to what is 
done than the prices paid.  But the vast number of outpatient claims makes an exact 
division difficult to determine. 
Of course, there is power in explaining service use beyond just the single cut of 
above or below median differential distance.  In the first stage of the IV estimation, I 
break the differential distance into 15 buckets (as in MMN): 0, <1 mile, 1-2 miles, 2-4 
miles, 4-6 miles, 6-8 miles, 8-10 miles, 10-12 miles, 12-15 miles, 15-18 miles, 18-21 
miles, 21-25 miles, 25-30 miles, 30-40 miles, and 40+ miles.  Table 4 shows the first 
stage equations predicting receipt of revascularization or admission to a high volume 
hospital.
12  The coefficients are generally as expected.  In virtually all cases, increases in 
                                                 
12 In practice, both differential distance measures are used to predict each outcome.  Controlling for 
differential distance to a revascularization facility, differential distance to a high volume hospital does not 
affect receipt of revascularization therapy.  Similarly, differential distance to a revascularization hospital   21
differential distance are associated with a reduced probability of receiving that type of 
care.  In the case of revascularization, for example, a person living 15 or more miles 
away from a revascularization facility is 5 percentage points less likely to receive a 
revascularization than is a person whose nearest hospital is capable of providing 
revascularization.  In the case of a high volume hospital, the differential distance impact 
is 74 percentage points at 15 miles.   
Table 5 shows the second stage estimation results.  For readability, the 
coefficients are graphed in Figure 2 (the impact on survival) and Figure 3 (the impact on 
costs).  The non-distance covariates (not shown) are as expected.  Older people, men, and 
people with more prior conditions are more likely to die than their opposites.   
The impact of revascularization is broadly similar to the Wald estimates derived 
from Table 3.  The marginal person receiving a revascularization is about 4 percentage 
points more likely to survive the first day after the MI than if the person did not receive a 
revascularization (although not statistically significantly).  This gap narrows over time 
and even reverses by 1 year.  At that time interval, people who received revascularization 
are 6 percentage points more likely to have died than people not receiving 
revascularization. 
After one year, a new gap in survival develops, in favor of those receiving 
revascularization.  By two years post-MI, people who receive a revascularization 
procedure are 3 percentage points more likely to be alive.  After 7 years, the impact is 12 
percentage points and is statistically significant.  The gap remains about 12 percentage 
points through 12 years after the MI.  As overall mortality increases, the gap narrows a 
                                                                                                                                                 
has little impact on admission to a high volume hospital when controlling for differential distance to a high 
volume hospital.   22
bit.  By 17 years after the MI, the mortality benefit for those receiving revascularization 
is 5 percentage points and is not statistically significant. 
It is difficult to know what accounts for this survival pattern.  It could be a real 
trend of treatment.  Some patients will be saved by primary PTCA.  Other patients might 
die during the revascularization procedure, or as a result of complications from it.
13  
Mortality could then decline as one-year survivors are at lower risk of recurrent episodes. 
But selection of patients or correlated treatments is also a concern.  MMN argue 
that the reduction in one-day mortality was likely due to treatments other than intensive 
surgical care that hospitals capable of providing that care also provide.  McClellan and 
Newhouse (1987) argue that this is true about hospitals opening catheterization labs as 
well, suggesting the treatments are cardiac ones.  If one believes that these other factors 
are important but are fully accounted for by the one-day survival difference, the 
subsequent 8 percentage point reduction in mortality after the first day (or 14 percent 
reduction from one year) truly reflects the impact of revascularization.   
Correlated treatments might be a concern after the MI as well.  It may be that 
hospitals that provide revascularization are also better at post-acute follow-up – greater 
attention to diet and exercise, or an increased use of medications to prevent recurrent 
MIs.  The Medicare data do not have evidence on this; these treatments are generally 
pharmaceuticals, and outpatient pharmaceuticals were not covered by Medicare at that 
time.  Other evidence suggests that revascularization hospitals are unlikely to be superior 
in providing this care, however.  Chandra and Staiger (2007) show that areas with higher 
cardiac catheterization rates in the mid-1990s were less likely to provide valuable 
                                                 
13 Restenosis, or re-occlusion of the coronary arteries, was a relatively common outcome of angioplasty 
during this time period.     23
medications to heart attack patients when they were inpatients.  The evidence would have 
to be the opposite at the hospital level to explain the results here.   
Alternatively, the correlated therapy might be provided years later.  People who 
go to a hospital for an MI are likely to go there for other problems as well.  Thus, cancers, 
broken hips, and pneumonias are more likely to be treated in these intensive hospitals.  If 
quality is correlated across diseases, these hospitals might be better at other treatments as 
well.  The possibility that care for conditions other than the heart attack explains the 
longer-term survival improvements could be tested with enough information on 
subsequent conditions and treatments received.  This analysis would require a complex 
model of the range of medical conditions, however.  Such a model does not now exist.  
As a crude proxy, the regressions presented above control for pre-existing conditions as 
of the MI.  Exploring this possible correlation is a valuable subject for future research. 
Figure 3 shows the impact of revascularization and admission to a high volume 
hospital on Medicare spending.  Medicare spending is significantly higher for the 
revascularization group than the group not receiving revascularization.  In the 90 days 
after the MI, the revascularization group spends $28,308 more.  This matches closely the 
mean reimbursement differential for revascularization therapy noted above, suggesting 
the estimate is plausible.  Incremental spending rises to $30,149 by one year after the MI 
and remains at that level for the next six years.  It is possible that this relative constancy 
reflects the higher end of life costs for the non-revascularization patients.  Those patients 
die sooner, and thus incur the higher costs of end of life care.  After 7 years, the cost gap 
increases, to a level of about $40,000 by year 10.       24
The impact of being admitted to a high volume hospital is significantly smaller 
than the impact of receiving revascularization.  The mortality impact is nearly 2 
percentage points in the first day (statistically significant), but then declines to 0.5 
percentage points by two years (not statistically significant).  It remains close to that level 
through the rest of the sample.  Being admitted to a high volume hospital is associated 
with increased spending, with an amount that is increasing over time.  The initial 
difference is about $2,000, and rises to $10,000 by year 13.   
 
V. Alternative  Specifications 
  I have estimated a variety of alternative models to test the robustness of the basic 
IV results.  I present some of these specification tests for the revascularization 
coefficients, since that therapy has the larger impact on survival and costs.   
  The first issue is the time frame in which revascularization is measured.  While 
considering 90 day procedure rates is standard in the literature, extending the time frame 
reduces the discriminatory power of differential distance – since consultation with 
providers in the community will result in additional procedures being performed for those 
initially admitted to non-revascularization hospitals.  A sharper test thus looks at care 
provided closer to the time of initial admission.  To consider this, I estimate models for 
the impact of revascularization within 7 days and 30 days of the MI.  The results are 
shown in the second and third rows of Table 6 (the first row repeats the results in Table 5, 
for convenience).   
Narrowing the window for the revascularization has little quantitative impact on 
the findings.  There is still a one day survival improvement for people receiving a   25
catheterization, ranging between 3 and 4 percentage points.  By one year after the MI, 
mortality is higher for the revascularization group, by 6 to 10 percentage points.  Over the 
next few years, patients receiving revascularization fare better, with a mortality benefit of 
11 to 12 percentage points after a decade and declining after that. 
  The costs associated with revascularization are somewhat smaller for 
revascularizations that occur closer in time to the MI.  Relative to the $30,000 additional 
cost in the first year for the baseline specification, the first year cost is $17,000 for the 
group receiving revascularization in the first week after the MI, and $26,000 for the 
group receiving revascularization within a month.  This may reflect that patients who 
wait longer for revascularization are on average sicker. 
  The next rows separate the revascularization impact by urban and rural residence.  
Revascularization may have a different impact in urban and rural areas.  Time to the 
hospital varies with urban/rural location, influencing how sick patients are when first 
treated.  In addition, surgeons may have more experience with revascularization in urban 
areas, and thus better outcomes.  As table 6 shows, survival benefits are significantly 
greater in urban areas than in rural ones.  The increase in mortality in the first year is 
greater in rural areas than in urban ones.  Further, the 10 year survival benefit is 16 
percent in urban areas, while there is no survival benefit in rural areas. 
  The final specification I examine reformulates the problem to consider the issue 
of correlated treatments.  As long as patients do not choose where to live on the basis of 
their potential benefits from intensive care, the regressions will accurately capture the 
impact of having been initially admitted to a hospital capable of performing 
revascularization.  By instrumenting for initial admission to a revascularization hospital   26
rather than just receiving a revascularization, I can estimate the impact of the full range of 
therapies associated with early adopters of revascularization technology.   
  These results are shown in the last row of Table 6.  The pattern of coefficients is 
generally similar to the estimates for revascularization, but the magnitudes are lower.  
Mortality for those initially admitted to a revascularization-capable hospital is higher 
after one year, but then declines in subsequent years.  The gap is one percentage point 
after 6 years and remains there for most of the next decade.  The similar qualitative 
pattern is encouraging.  The lower quantitative magnitude is a natural product of the 
analysis, and can be seen most clearly in the revascularization columns of table 3.  The 
regression for receiving a revascularization attributes the half-percent or so better 
mortality profile for people living near revascularization hospitals to the 3 percentage 
point higher revascularization rates for those living closer to such facilities.  In the 
regression for being admitted to a revascularization hospital, in contrast, the same 
mortality difference is instead attributed to the 38 percentage point difference in where 
people are admitted.  The impact of admission is obviously smaller.   
Corresponding to this smaller mortality impact is a lower cost associated with 
admission.  Table 6 shows that cumulative spending is about $1,400 higher for those 
admitted to a hospital capable of performing revascularization.   
 
VI.   Implications 
There are two ways to interpret the results in the previous section.  The first is that 
they largely reflect the true impact of revascularization.  Using the values presented, we 
can estimate the incremental lifetime cost-effectiveness of revascularization therapy.    27
Standard lifetable methods indicate that the greater survival for the marginal patients 
receiving revascularization translates into 1.1 years of additional life expectancy.
14  The 
cost of this gain is about $38,000.  Thus, the cost per year of life is $33,246.  Admission 
to a high volume hospital is substantially less cost effective.  The increase in life 
expectancy is only 0.06 years, and the incremental cost is nearly $10,000.  The cost per 
year of life is thus $175,719.   
The value of a year of life is generally taken to be about $100,000 (Cutler, 2004).  
That value typically assumes good quality of life; the quality here may not be as high.  
However, these calculations ignore any improvements in quality of life that may result 
from revascularization.  For non-primary angioplasty in particular, that is a big part of the 
potential benefits.  Thus, it is not clear whether accounting for quality would lead to more 
or less favorable cost-effectiveness ratios.  Overall, it is virtually certain that 
revascularization after an MI is highly cost-effective. 
The unresolved issue in this first interpretation is whether the benefits of 
revascularization flow from that therapy, or from receipt of other services that are 
correlated with admission to a hospital with revascularization capabilities.  If it is the 
latter, the results reflect the current and future implications of an initial admission to a 
high-tech hospital, but not necessarily receipt of those procedures.  In this case, the 
mortality benefit is smaller, but so are costs.  The estimates in the last row of Table 6 
translate into a benefit of .08 years at a cost of $1,389, or $17,022 per year of additional 
life.  Care is clearly worth it, but which care is an open question.   
                                                 
14 This assumes that people who survive 17 years all die in the next year.  The 1.1 year survival 
improvement is not particularly sensitive to this assumption.   28
The obvious issue is how these estimates compare to others in the literature.  
MMN do not estimate the cost of catheterization, but other studies do.  As noted above, 
McClellan and Newhouse (1987) estimate that costs are about $70,000 per patient 
surviving an additional year.  Since the average heart attack survivor lives 5 years in our 
data, this is about $14,000 per lifeyear.  Cutler and McClellan (2001) use time series data 
to estimate a cost of about $10,000 per additional year of life.  The estimates are very 
close to what I present.   
The biggest empirical puzzle raised by these results is the extent to which the 
improved outcomes reflect intensive treatment of the heart attack versus less intensive 
treatment, or treatment of other conditions.  Without better treatment data and a detailed 
analysis of the full range of subsequent conditions, I cannot answer the question 
definitively.  Separating out the impact of high tech care from other care is a topic worthy 
of future research. 
   29
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Table 1: Average Medical Spending by Time Until 
Death 
  Time until death 
Payer and Age  <12 months  >12 months 
All Payers     
     Total  $37,561  $7,456 
     65-74  37,043  5,719 
     75-84  38,529  7,832 
     85+ 
 
36,985 13,895 
Medicare    
     Total  $26,049  $3,786 
     65-74  27,832  3,247 
     75-84  26,078  4,153 
     85+ 
 
18,226 5,052 
Non-Medicare    
     Total  $11,512  $3,670 
     65-74  9,211  2,472 
     75-84  12,451  3,679 
     85+  18,689  8,843 
Note: Data are from Hoover et al. (2002).  The 
average is adjusted to the age distribution of the 
entire elderly population. 
 
 
  
 
 
 
 
Table 2: Differential Distance Measures 
  
Measure 
Revascularization 
hospital 
High volume 
hospital 
   Mean  18.7  12.8 
   10
th %ile  0.0  0.0 
   25
th %ile  1.1  0.0 
   50
th %ile  7.8  1.9 
   75
th %ile  29.9  19.7 
   90
th %ile  51.3  44.4 
  
Correlations 
     
   Revasc hospital  1.000  --- 
   High volume hospital .640  1.000 
Note: Hospitals are counted as having the capacity to 
perform revascularization if they do at least 2 procedures in 
the year in question.  A high volume hospital is one with at 
least 15 admissions for MI in the year. 
 
 
 
  
 
 
 
Table 3: Differences in Patient Characteristics by Differential Distance Measures 
   Revascularization  High Volume 
 Characteristic  < 8 miles > 8 miles p-value  < 2 miles  > 2 miles  p-value 
Demographics           
   Average age  76.2  76.1  .072  76.2  76.1  .349 
   Percent male  49%  52%  <.001  49%  51%  <.001 
   Percent black  7%  4%  <.001  6%  5%  <.001 
   Percent other race / 
    unknown 
1.2% 0.8% <.001 0.9%  1.1%  .026 
   Percent rural  4%  59%  <.001  11%  52%  <.001 
   Prior year spending  $3,124  $2,442  <.001  $3,035  $2,530  <.001 
 
Hospital of initial admission 
        
   Revasc hospital  47%  9%  <.001  35%  21%  <.001 
   High volume hospital  65%  36%  <.001  80%  29%  <.001 
 
Procedure receipt 
         
   Cath Within 90  26%  21%  <.001  24%  24%  .354 
   CABG within 90  9%  7%  <.001  8%  8%  .252 
   PTCA within 90  6%  4%  <.001  5%  5%  .057 
   Revasc within 90  14%  11%  <.001  13%  13%  .957 
 
Cumulative Mortality 
        
1 day  7.8%  8.9%  <.001  7.7%  9.0%  <.001 
180 Days  34.6%  35.3%  0.007  34.2%  35.8%  <.001 
1 year  39.9%  40.3%  0.214  39.6%  40.7%  <.001 
5 years  62.5%  62.9%  0.244  62.5%  62.9%  .094 
10 years  79.8%  80.3%  0.041  79.9%  80.2%  .090 
17 years  93.4%  93.7%  0.008  93.4%  93.7%  .006 
 
Cumulative Costs 
         
30  Days  $16,045 $12,820  <.001 $15,532 $13,290 <.001 
180  Days  $19,354 $15,386  <.001 $21,531 $17,826 <.001 
Year  1  $26,441 $20,615  <.001 $25,912 $21,059 <.001 
Year  5  $45,497 $36,043  <.001 $44,909 $36,490 <.001 
Year  10  $60,986 $48,977  <.001 $59,927 $49,861 <.001 
Year  17  $73,051  $59,800  <.001 $72,029 $60,628 <.001 
              
N,  Costs  14,864  15,124  - 15,099  14,889 - 
N, All Other  62,983  61,967  -  63,327  61,623  - 
Note: Cost sample excludes those enrolled in an HMO at any point after the MI 
  
 
 
 
Table 4: First Stage Instrumental Variable Results 
   Outcome 
  
Variable 
Received 
Revascularization 
Admitted to High 
Volume Hospital 
Differential Distance       
0 mile  Reference  Reference 
<1 mile  -0.0112 
(-2.28) 
-0.1482 
(-28.58) 
1-2 miles  -0.0306 
(-6.90) 
-0.2684 
(-53.05) 
2-4 miles  -0.0294 
(-7.73) 
-0.3853 
(-84.96) 
4-6 miles  -0.0348 
(-8.12) 
-0.5187 
(-86.87) 
6-8 miles  -0.0403 
(-7.83) 
-0.6159 
(-88.78 ) 
8-10 miles  -0.0482 
(-8.16) 
-0.6543 
(-81.43) 
10-12 miles  -0.0629 
(-9.71) 
-0.6999 
(-83.21) 
12-15 miles  -0.0439 
(-8.06) 
-0.7449 
(-101.12) 
15-18 miles  -0.0509 
(-8.78) 
-0.7423 
(-96.15) 
18-21 miles  -0.0592 
(-10.03) 
-0.7654  
(-100.53) 
21-25 miles  -0.0589 
(-10.88) 
-0.7855 
(-114.94) 
25-30 miles  -0.0584 
(-11.37) 
-0.7929 
(-118.07) 
30-40 miles  -0.0726 
(-16.06) 
-0.8079 
(-141.27) 
40+ miles 
 
-0.0799 
(-19.25) 
-0.8514 
(-180.61) 
Demographics, health 
status controls  Yes Yes 
N 124,950  124,950 
R
2 0.077  0.434 
Note:  The coefficients report the impact of differential distance to the 
relevant outcome on the probability of receiving that outcome (e.g., 
the impact of differential distance to a revascularization facility on 
receipt of revascularization).  t-statistics are in parentheses.  Each 
regression also includes differential distance to hospitals of the other 
type.  Those coefficients are not reported.   
  
 
Table 5: Impact of Medical Care on Survival After an MI 
   Revascularization  High Volume Hospital 
Time After MI  Survival  Spending  Survival  Spending 
1 day  -0.042 
(-1.08)  -  -0.0192 
(-6.84)  - 
7 days  -0.020 
(-0.38)  -  -0.0224 
(-5.80)  - 
30 days  -0.029 
(-0.47) 
$24,544 
(4.84) 
-0.0195 
(-4.46) 
$1,688 
(4.53) 
90 Days  -0.004 
(-0.06) 
$28,308 
(4.57) 
-0.0185 
(-4.02) 
$2,301 
(5.07) 
180 days  0.053 
(0.81) 
$28,593 
(4.14) 
-0.0152 
(-3.20) 
$3,152 
(6.22) 
1 year  0.061 
(0.91) 
$30,149 
(3.28) 
-0.0097 
(-2.02) 
$4,065 
(6.04) 
2 years  -0.029 
(-0.44) 
$27,339 
(2.52) 
-0.0055 
(-1.13) 
$5,300 
(6.65) 
3 years  -0.067 
(-1.02) 
$25,919 
(2.16) 
-0.0049 
(-1.04) 
$5,993 
(6.81) 
4 years  -0.043 
(-0.66) 
$26,820 
(2.07) 
-0.0014 
(-0.30) 
$6,560 
(6.90) 
5 years  -0.106 
(-1.68) 
$27,517 
(1.99) 
-0.0053 
(-1.16) 
$7,296 
(7.18) 
6 years  -0.118 
(-1.94) 
$29,662 
(2.03) 
-0.0050 
(-1.13) 
$7,659 
(7.15) 
7 years  -0.119 
(-2.02) 
$31,090 
(2.03) 
-0.0048 
(-1.12) 
$7,953 
(7.07) 
8 years  -0.108 
(-1.89) 
$32,919 
(2.05) 
-0.0042 
(-1.02) 
$7,982 
(6.79) 
9 years  -0.111 
(-2.03) 
$36,961 
(2.21) 
-0.0058 
(-1.47) 
$8,087 
(6.59) 
10 years  -0.119 
(-2.28) 
$38,028 
(2.16) 
-0.0073 
(-1.95) 
$8,314 
(6.45) 
11 years  -0.113 
(-2.27) 
$38,191 
(2.08) 
-0.0061 
(-1.70) 
$8,532 
(6.33) 
12 years  -0.120 
(-2.55) 
$40,804 
(2.13) 
-0.0088 
(-2.59) 
$9,002 
(6.40) 
13 years  -0.074 
(-1.68) 
$38,079 
(1.91) 
-0.0060 
(-1.88) 
$9,161 
(6.26) 
14 years  -0.064 
(-1.55) 
$38,708 
(1.89) 
-0.0061 
(-2.03) 
$9,671 
6.44) 
15 years  -0.047 
(-1.21) 
$36,758 
(1.75) 
-0.0053 
(-1.90) 
$9,524 
(6.19) 
16 years  -0.041 
(-1.15) 
$37,200 
(1.75) 
-0.0060 
(-2.31) 
$9,599 
(6.14) 
17 years  -0.051 
(-1.52) 
$37,990 
(1.76) 
-0.0068 
(-2.83) 
$9,770 
(6.17) 
 Note: Each cell is a separate regression of either cumulative mortality or spending.  
All regressions include controls for age/sex, race, distance to the nearest hospital, prior 
year spending, and 24 conditions.  t-statistics are in parentheses. 
 Table 6: Alternative Specifications of Impact of Revascularization on Mortality and Costs 
 Mortality    Costs 
Specification  1 day  90 days  1 year  10 years 17 years 90 days  1 year  10 years  17 years 
Baseline -0.042 
(-1.08) 
-0.004 
(-0.06) 
0.061 
(0.91) 
-0.119 
(-2.28) 
-0.051 
(-1.52) 
$28,308 
(4.57) 
$30,149 
(3.28) 
$38,028 
(2.16) 
$37,990 
(1.76) 
Timing of Revascularization 
            
  7 day revasc  -0.027 
(-0.63) 
0.019 
(0.28) 
0.095 
(1.31) 
-0.110 
(-1.92) 
-0.031 
(-0.84) 
$19,382 
(2.64) 
$16,844 
(1.61) 
$19,443 
(0.98) 
$16,872 
(0.69) 
  30 day revasc  -0.036 
(-0.97) 
0.000 
(-0.01) 
0.061 
(0.95) 
-0.113 
(-2.22) 
-0.042 
(-1.31) 
$25,346 
(3.84) 
$25,961 
(2.69) 
$31,517 
(1.72) 
$33,264 
(1.48) 
Urban-Rural Residence 
            
   Urban  -0.033 
(-0.81) 
-0.029 
(0.42) 
0.036 
(0.72) 
-0.164 
(-2.93) 
-0.065 
(0.036) 
$23,159 
(3.11) 
$21,268 
(1.91) 
$28,205 
(1.38) 
$32,379 
(1.31) 
   Rural  -0.071 
(-0.78) 
0.036 
(0.25) 
0.088 
(0.58) 
0.004 
(0.035) 
-0.002 
(-0.02) 
$23,691 
(3.83) 
$24,343 
(2.89) 
$48,950 
(2.23) 
$55,828 
(2.10) 
Instrument for Initial Admission to High-Tech Hospital 
    
  High tech 
     hospital admit 
-0.0003 
(-0.09) 
0.0027 
(0.46) 
0.0077 
(1.27) 
-0.0096 
(-2.00) 
-0.0020 
(-0.64) 
$1,408 
(2.23) 
$1,150 
(1.28) 
$1,287 
(0.76) 
$1,389 
(0.67) 
Note: Each cell reports the coefficient from a regression of mortality or costs on revascularization.  Other controls are 
the same as in Table 5.  t-statistics are in parentheses. 
 
 
 
 
  
 
 
Figure 1: OLS Estimates of the Impact of Revascularization and 
High Volume Hospital Admission on Cumulative Mortality
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Figure 2: IV Estimates of the Impact of Revascularization and 
High Volume Hospital Admission on Cumulative Mortality
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Figure 3: IV Estimates of the Impact of Revascularization and 
High Volume Hospital Admission on Cumulative Spending
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